COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects With Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either Carvedilol CR + Lisinopril or Lisinopril Monotherapy

Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (<140/90mmHg) at Baseline. Subjects will be randomized to receive either carvedilol CR + lisinopril or lisinopril + placebo. Subjects will be uptitrated over a 6 week period until target blood pressure (<140/90mmHg) is met. The primary objective of the study is to compare the proportion of subjects who achieve target blood pressure after 6 weeks of treatment.

本研究为一项针对基线未达目标血压（<140/90mmHg）的1期或2期原发性高血压（essential hypertension）受试者的随机、双盲、平行组、多中心临床试验。受试者将被随机分配至两个治疗组：一组接受卡维地洛控释制剂（carvedilol CR）联合赖诺普利（lisinopril）治疗，另一组接受赖诺普利联合安慰剂（placebo）治疗。受试者将在6周周期内进行剂量滴定，直至达到目标血压（<140/90mmHg）。本试验的主要研究目的为比较治疗6周后达到目标血压的受试者比例。